Zydus Gets First Canada Nod for Drug

  Published 10 months ago

Zydus received its first NOC from Health Canada for ZDS-Varenicline, aiding smoking cessation, with production in Ahmedabad.

  • ZDS-Varenicline (0.5 & 1 mg) targets smoking addiction by partially activating nicotinic acetylcholine receptors in the brain.
  • Tablets to be manufactured at Zydus Lifescience SEZ unit in Ahmedabad, marking a milestone for the group in Canada.
  • Varenicline tablets saw annual sales of CAD 15 million in Canada as of December 2024 (IQVIA MAT).
You might like these

Gland Pharma Shock Drug Hits $45M Sales

L&T Secures Rs 15,000 Cr Offshore Order

Biocon Launches Nepexto in Australia

eShram Crosses 30.95 Cr Registrations

BCPL Railway Infrastructure Stock Rises

Siri Fort Auditorium Renovation Project Launched

IndusInd Bank, DPIIT Ink Deal to Support Startups

News that matters the most ⚡